Genmab A/S (GMAB)
25.14
-0.44
(-1.72%)
USD |
NASDAQ |
Jun 28, 16:00
25.12
-0.02
(-0.08%)
After-Hours: 20:00
Genmab Enterprise Value: 11.72B for June 28, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 28, 2024 | 11.72B |
| June 27, 2024 | 12.00B |
| June 26, 2024 | 12.05B |
| June 25, 2024 | 12.12B |
| June 24, 2024 | 12.15B |
| June 21, 2024 | 12.28B |
| June 20, 2024 | 12.27B |
| June 18, 2024 | 12.22B |
| June 17, 2024 | 12.21B |
| June 14, 2024 | 12.47B |
| June 13, 2024 | 12.68B |
| June 12, 2024 | 12.91B |
| June 11, 2024 | 13.27B |
| June 10, 2024 | 13.65B |
| June 07, 2024 | 13.56B |
| June 06, 2024 | 14.06B |
| June 05, 2024 | 14.19B |
| June 04, 2024 | 14.03B |
| June 03, 2024 | 14.24B |
| May 31, 2024 | 13.84B |
| May 30, 2024 | 13.77B |
| May 29, 2024 | 13.77B |
| May 28, 2024 | 13.78B |
| May 24, 2024 | 13.78B |
| May 23, 2024 | 14.66B |
| Date | Value |
|---|---|
| May 22, 2024 | 14.96B |
| May 21, 2024 | 14.54B |
| May 20, 2024 | 14.89B |
| May 17, 2024 | 15.07B |
| May 16, 2024 | 14.86B |
| May 15, 2024 | 15.23B |
| May 14, 2024 | 14.78B |
| May 13, 2024 | 14.56B |
| May 10, 2024 | 14.35B |
| May 09, 2024 | 14.33B |
| May 08, 2024 | 14.32B |
| May 07, 2024 | 14.64B |
| May 06, 2024 | 14.47B |
| May 03, 2024 | 14.91B |
| May 02, 2024 | 13.64B |
| May 01, 2024 | 14.31B |
| April 30, 2024 | 13.62B |
| April 29, 2024 | 14.19B |
| April 26, 2024 | 13.92B |
| April 25, 2024 | 13.53B |
| April 24, 2024 | 14.18B |
| April 23, 2024 | 14.24B |
| April 22, 2024 | 14.51B |
| April 19, 2024 | 14.33B |
| April 18, 2024 | 14.13B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
9.501B
Minimum
Mar 16 2020
28.99B
Maximum
Sep 03 2021
19.21B
Average
20.19B
Median
Enterprise Value Benchmarks
| Novo Nordisk A/S | 638.28B |
| Ascendis Pharma A/S | 8.166B |
| Galecto Inc | -13.72M |
| Evaxion Biotech AS | 3.958M |
| IO Biotech Inc | -40.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 193.00M |
| Revenue (Quarterly) | 603.46M |
| Total Expenses (Quarterly) | 486.79M |
| EPS Diluted (Quarterly) | 0.2939 |
| Gross Profit Margin (Quarterly) | 95.53% |
| Profit Margin (Quarterly) | 31.98% |
| Earnings Yield | 4.80% |
| Operating Earnings Yield | 5.00% |
| Normalized Earnings Yield | 4.456 |